Agilent Technologies, Inc. (NYSE:A) Shares Acquired by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. grew its stake in Agilent Technologies, Inc. (NYSE:A) by 1.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 10,771 shares of the medical research company’s stock after purchasing an additional 194 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Agilent Technologies were worth $1,447,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Massachusetts Financial Services Co. MA grew its position in shares of Agilent Technologies by 3.5% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 15,589,874 shares of the medical research company’s stock valued at $2,314,784,000 after buying an additional 525,214 shares during the last quarter. State Street Corp grew its position in shares of Agilent Technologies by 1.2% during the 3rd quarter. State Street Corp now owns 12,819,897 shares of the medical research company’s stock valued at $1,903,498,000 after buying an additional 158,175 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Agilent Technologies by 0.4% during the 3rd quarter. Geode Capital Management LLC now owns 6,948,679 shares of the medical research company’s stock valued at $1,028,241,000 after buying an additional 30,610 shares during the last quarter. Van ECK Associates Corp grew its position in shares of Agilent Technologies by 8.7% during the 4th quarter. Van ECK Associates Corp now owns 3,235,263 shares of the medical research company’s stock valued at $434,625,000 after buying an additional 258,358 shares during the last quarter. Finally, Nordea Investment Management AB grew its position in shares of Agilent Technologies by 2.6% during the 4th quarter. Nordea Investment Management AB now owns 3,198,715 shares of the medical research company’s stock valued at $431,603,000 after buying an additional 80,819 shares during the last quarter.

Agilent Technologies Trading Down 1.2 %

Agilent Technologies stock opened at $126.36 on Tuesday. The firm has a 50 day simple moving average of $140.48 and a 200-day simple moving average of $139.08. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.20 and a quick ratio of 1.66. The stock has a market capitalization of $36.05 billion, a PE ratio of 29.05, a price-to-earnings-growth ratio of 3.59 and a beta of 1.11. Agilent Technologies, Inc. has a 12-month low of $124.16 and a 12-month high of $155.35.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Wednesday, February 26th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.04. The business had revenue of $1.68 billion during the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. As a group, equities research analysts expect that Agilent Technologies, Inc. will post 5.57 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st will be paid a dividend of $0.248 per share. This represents a $0.99 annualized dividend and a yield of 0.79%. The ex-dividend date is Tuesday, April 1st. Agilent Technologies’s dividend payout ratio is presently 22.76%.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on A. Robert W. Baird lowered their price objective on shares of Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating for the company in a research report on Thursday, February 27th. Barclays upgraded shares of Agilent Technologies from an “underweight” rating to an “equal weight” rating and upped their target price for the stock from $135.00 to $145.00 in a research report on Monday, February 10th. StockNews.com upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, December 24th. Bank of America decreased their target price on shares of Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a research report on Tuesday, November 26th. Seven research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, Agilent Technologies has a consensus rating of “Moderate Buy” and a consensus target price of $146.15.

Insider Activity at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 1,911 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total value of $286,650.00. Following the completion of the sale, the chief executive officer now owns 39,652 shares in the company, valued at approximately $5,947,800. This represents a 4.60 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.